Selank Peptide Overview

Research suggests that Selank may exhibit certain neuroprotective characteristics. Selank peptide may support mood and potentially decrease stress hormone secretion.

According to research, 84 genes have been linked to GABA signaling.^[2] Selank peptide potentially regulates 7 genes, while 45 genes may induce change in expression. The net result suggests that 52 genes tied to GABA signaling may be impacted by Selank to a certain degree, suggesting that Selank may directly modulate gene expression in nerve cells and impact changes by influencing the affinity of the GABA receptor for GABA.

The impact of Selank on enkephalin degradation may potentially regulate effects on GABA receptors. According to scientific data, research models exhibit increased enkephalinase activity in the blood after stress hormone secretion, resulting in short half-lived enkephalins.

Selank peptide potentially resets the enzymatic pathway to protect the natural anxiolytic peptides by inhibiting enkephalin degradation. The research proposes that part of the Selank action may be from a preventive impact on enkephalin degradation.

Selank Peptide and Memory

Scientists believe Selank peptide may enhance certain cognitive processes.^[3] Training mice with rewards, such as food, in combination with Selank, may potentially boost memory trace stability and storage. Selank’s impact in these mice models, despite anxiety levels, indicates that the peptide goes a long way to lower stress-related memory impairment.

Selank peptide may also potentially alter memory by regulating gene expression in the hippocampus. Research suggests changes in mRNA levels of 36 varying genes. Most genes encode proteins relating to the plasma membrane, regulating ion-dependent processes in memory and learning.

According to studies, Selank may potentially salvage learning and memory recall. Exposing mice samples to a neurotoxin and Selank suggested a restoration of cognitive processes. This potential correlates with an artificial inhibition of the catecholamine system in the brain via Selank. Scientists believe that Selank peptide may offer cognitive support following traumatic brain injury.

Selank Peptide and Pain Perception

Selank peptide may potentially inhibit enzymes in the blood that induce enkephalin synthesis, reducing natural enkephalin degradation. Enkephalins are peptides that bind to opioid receptors, reducing the severity of pain. They also regulate stress response and are at abnormally high levels in the adrenal glands and brain. Therefore, Selank peptide may possibly modulate stress response and its impacts on learning, concentration, and memory by lowering enkephalin levels in the brain.

Selank and the Immune System following Anxiety

Selank peptide may potentially suppress genes that control inflammatory cytokine inflammation, IL-6, in research models of depression.^[4] Selank’s research in mice models suggests that the peptide may control the expression of 34 genes that influence the inflammatory process. These genes may impact cytokines, chemokines, and both receptors. Specifically, Selank peptide modulates Bcl6 expression, a gene that controls immune system development.

In addition, Selank peptide and Selank fragments may temporarily influence gene expression for Xcr1, C3, CAsp1, and II2rf in the mouse spleen. Selank may affect the immune system balance and inflammation by impacting these genes.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

1. Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. Russian. PMID: 25176261.
2. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank peptide Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016 Feb 18;7:31. doi: 10.3389/fphar.2016.00031. PMID: 26924987; PMCID: PMC4757669.
3. Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskii II, Zuikov AV. Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny. Bull Exp Biol Med. 2007 Nov;144(5):689-91. doi: 10.1007/s10517-007-0406-2. PMID: 18683497.
4. Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, Gabaeva MV, Sokolov OIu, Zozulia AA, Ershov FI. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-5. Russian. PMID: 18577961.

Ipamorelin & Sermorelin Blend

Researchers suggest that endogenous growth hormone production may increase under the influence of Ipamorelin and Sermorelin in animal research models. It is hypothesized that Sermorelin may exhibit different mechanisms of action in the pituitary gland than Ipamorelin. As a result, a higher growth hormone level may be obtained upon combinatorial introduction of Ipamorelin and Sermorelin.

Ipamorelin

Ipamorelin is considered by researchers to be the most direct ghrelin analog or agonist of the growth hormone secretagogue. The peptide appears to potentially increase serum growth hormone levels in certain animals.^[1] Ipamorelin appears to stimulate the pituitary gland-based secretion of growth-related secretions. It is suggested to be impactful in skeletal and muscular tissue growth and repair.

Ipamorelin may potentially stimulate the production of insulin-like growth factor 1 (IGF-1), which may increase contractile force in muscle fibers. According to studies, Ipamorelin does not appear to affect cortisol, ghrelin, or prolactin levels.^[3] The researchers also reported that “Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future [research].”

Sermorelin

Sermorelin is a growth hormone analog that researchers suggest mimics the primary function of GHRH while avoiding the ancillary action. Sermorelin, like the natural GHRH mechanism, appears to bind to the growth hormone-releasing hormone receptor (GHRHr) in the anterior pituitary gland.^[4] The peptide may increase endogenous IGF-1 secretion while potentially promoting robust growth hormone production.

A negative feedback mechanism induced by somatostatin may control the positive effect of Sermorelin on the release of the growth hormone. Somatostatin is a growth-inhibiting hormone (GHIH) that may inhibit the secretion of other hormones in the endocrine system as well as certain exocrine secretions.

Sermorelin’s natural action mechanism may preserve the hypothalamic-pituitary-somatotropic axis, preventing the cessation of direct replacement with hGH.

Sermorelin is researched for its potential to influence growth hormone secretion.^[5] The researchers report that “Sermorelin stimulates pituitary gene transcription of hGH messenger RNA, increasing pituitary reserve and thereby preserving more of the growth hormone neuroendocrine axis, which is the first to fail during aging.” The peptide may improve bone density, renal function, seizure activity, the adverse action of dementia, and scarring caused by a heart attack. Sermorelin may also promote angiogenesis, reduce cardiomyocyte cell death, and reduce inflammation after cardiac injury. Sermorelin may also potentially improve sleep quality, the central nervous system, bone function, bowel motility, and diabetes insulin control.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.
 

References

1. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343.
2. Johansen PB, Segev Y, Landau D, Phillip M, Flyvbjerg A. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Exp Diabesity Res. 2003 Apr-Jun;4(2):73-81. doi: 10.1155/EDR.2003.73. PMID: 14630569; PMCID: PMC2478601.
3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
4. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999 Aug;12(2):139-57. doi: 10.2165/00063030-199912020-00007. PMID: 18031173.
5. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. doi: 10.2147/ciia.2006.1.4.307. PMID: 18046908; PMCID: PMC2699646.
6. Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021 Mar;9(5):406. doi: 10.21037/atm-20-6561. PMID: 33842627; PMCID: PMC8033379.

While inhibiting lipogenesis, AOD9604 may potentially stimulate and improve lipolysis (fat disintegration or breakdown). The peptide does not appear to affect IGF-1 or insulin levels and may not have any association in diabetes or glucose intolerance.^[1] Researchers comment that “chronic [exposure to] AOD9604 showed no adverse effect on insulin sensitivity of the animals, as [seen] with euglycemic clamp techniques.” There is also no data to suggest that the peptide leads to the formation of antibodies. ^[2]

AOD9604 and General Research

The peptide appears to stimulate the pituitary gland by acting directly on it. This appears to be the same mechanism of action as GH, as it mimics the actions of the natural growth hormone on body fat metabolism. AOD9604 has been suggested by researchers to accelerate fat-burning processes and restore anabolism by acting on the pituitary gland. The compound has not been implicated in appetite alteration or blood sugar levels.

AOD9604 research in mice suggested that the peptide may impact more than the beta-3-adrenergic receptors on white fat.^[4] The scientists suggested that “both hGH and AOD9604 are capable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice.” Initially, it was assumed that AOD9604 may increase the metabolic rate in fat cells by binding to these receptors and switching them from storage to user mode. However, even mice lacking these receptors appeared to have reduced fat cell accumulation after being exposed to AOD9604.

Because the beta-3-adrenergic receptor appears to influence fat loss through AOD9604, another mechanism may potentially be at work. The compound may indirectly stimulate apoptosis in white fat cells, according to this theory.

Finally, and tangentially, the peptide appears to have a potential impact in models of osteoarthritis due to alterations observed in the gross clinical exam and microscopic structure of cartilage in an arthritic joint model.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi: 10.1159/000053183. PMID: 11146367.
2. Stier, Heike, Evert Vos, and David Kenley. “Safety and tolerability of the hexadecapeptide AOD9604 in humans.” Journal of Endocrinology and Metabolism 3.1-2 (2013): 7-15.
3. Zieba R. Otyłość: przeglad aktualnie stosowanych leków i nowych zwiazków poddawanych ocenie klinicznej [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development]. Postepy Hig Med Dosw (Online). 2007 Oct 19;61:612-26. Polish. PMID: 17971763.
4. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213.
5. Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring). 2006 Jun;14 Suppl 3:143S-149S. doi: 10.1038/oby.2006.294. PMID: 16931496.
6. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694.

Palmitoyl Tripeptide-1, aka Pal-GHK or Palmitoyl Oligopeptide, is a hybrid peptide comprising a peptide and a fatty acid end. The peptide end is the GHK-end (Glycine, histidine, and lysine). Meanwhile, the fatty acid end is the Pal-end (Palmitoyl). Pal-GHK is a fibroblast stimulant and a small fraction of the elastin protein. It may potentially enhance the synthesis of elastin, collagen, and other extracellular matrix protein (ECM) in the connective tissues, bone, and skin.^[1]

The peptide (GHK) component of the Palmitoyl Tripeptide-1 peptide may subject fibroblasts into perceiving that elastin—one of the most abundant proteins in the ECM—is damaged. As a result, the organism may rapidly produce and multiply fibroblasts to replenish and regenerate the lost elastin. Palmitoyl Tripeptide-1 may also mitigate or prevent cell aging and re-energize fibroblasts in the ECM.

The fatty acid (Palmitoyl) end of Pal-GHK appears to serve as an intermediary, a transport complex that may perform at a higher level of impact when the GHK-end is attached to the Pal-end, resulting in potentially enhanced skin and cell penetration.

Palmitoyl Tripeptide-1 may stimulate genes that might alter and reset cells. This may potentially be possible by attaching Palmitoyl to the peptide sequence, GHK, which may make it overly effective for DNA repair genes and increases expression of the 14 genes that modulate antioxidant production.^[2] The researchers also note that “The Broad Institute’s Connectivity Map indicated that GHK induces a 50% or greater change of expression in 31.2% of … genes.” After the genetic changes, reduced action of cell aging and removing radicals and toxic agents that induce the development of age-related diseases might be attained.

Palmitoyl Tripeptide-1 may potentially aid in rapid tissue repair by enhancing the production of new blood vessels (angiogenesis) at injury sites. The peptide might also repair nerves and induces the growth of new nerves. Furthermore, Pal-GHK may better the actions of genes responsible for wound healing; it may activate DNA repair genes and suppresses genes that may aid cancer growth.

Scientific research has suggested that Palmitoyl Tripeptide-1 may protect the ECM by preventing cell death in certain cases. The peptide may potentiate this action by enhancing elastin and collagen production.

Palmitoyl Tripeptide-1 may potentially replenish the skin’s extracellular matrix, inducing wrinkle reduction and alleviation. At the same time, it may prevent collagen degradation following exposure to Ultraviolet A (UVA) rays.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

1. Goldsberry, S. & Garcines, L. Anti-aging cosmeceutical composition. (2013).
2. Pickart, L., Vasquez-Soltero, J. M. & Margolina, A. GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes. Cosmetics 2, 236–247 (2015). doi: 10.3390/cosmetics2030236
3. Trookman, N. S., Rizer, R. L., Ford, R., Mehta, R. & Gotz, V. Clinical assessment of a combination lip treatment to restore moisturization and fullness. J. Clin. Aesthetic Dermatol. 2, 44–48 (2009).
4. Dupont, E. et al. Clinical efficacy of a serum integrating multiple cosmetic ingredients in the management of erythema of the face in aging skin. J. Cosmet. Dermatol. 11, 207–212 (2012).
5. Bradley, E. J., Griffiths, C. E. M., Sherratt, M. J., Bell, M. & Watson, R. E. B. Over-the-counter anti-ageing agents and their ability to protect and repair photoaged skin. Maturitas 80, 265–272 (2015).

DSIP may potentially lower oxidative stress and restore normal myocardial contractility. Furthermore, the peptide may potentially produce mitigatory action against depressive disorders and cancer cell proliferation. DSIP has also been researched for its potential to inhibit Somatostatin secretion, modify corticotropin levels, actions on blood pressure, stress hormone secretion and pain perception.

DSIP and Sleep Pattern Regulation

Some research suggests DSIP promotes slow-wave sleep while suppressing paradoxical sleep. It may also cause arousal in the first hour of sleep and sedation in the second. Research findings suggest that DSIP might normalize sleep and modulate sleep cycle dysfunctions. Sleep research involving DSIP was conducted in research models of chronic insomnia, and DSIP reportedly improved sleep to the same level as normal controls. This study supports previous findings that DSIP may reduce sleep latency and promotes sleep structure in chronic insomnia.^[4] The scientists note that “The [exposure] substantially improved night sleep with the first and additionally with repeated [introduction].”

According to the research, DSIP may potentially increase sleep time by 59% compared to a placebo, and delay sleep onset.^[5] These findings, however, contradict the EEG analysis of the research models under examining, which revealed no sedation. However, this may potentially be due to current testing patterns, as many EEG measures of sedation are based on pharmacologic sedation rather than natural sedation.

DSIP and Metabolism

DSIP research in rat models suggests that the peptide may limit stress-induced metabolic disturbances that cause the mitochondria to switch from oxygen-dependent to oxygen-independent respiration. The latter may produce dangerous metabolic byproducts. DSIP may be employed in research related to conditions such as heart attack and stroke due to its potential to maintain oxidative phosphorylation even in hypoxic conditions.^[8] DSIP may mitigate metabolic damage caused by oxygen deprivation by preserving normal mitochondrial function, thereby protecting tissues until blood flow is restored. DSIP may potentially reduce free radical production by maintaining normal mitochondrial functions.

DSIP research further suggests that the peptide may inhibit somatostatin secretion, contributing to skeletal muscle hypertrophy and hyperplasia.
According to Delta Sleep Inducing Peptide research, the peptide may influence blood pressure, thermogenesis, the lymphokine system, and heart rate.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

1. Popovich IG, Voitenkov BO, Anisimov VN, Ivanov VT, Mikhaleva II, Zabezhinski MA, Alimova IN, Baturin DA, Zavarzina NY, Rosenfeld SV, Semenchenko AV, Yashin AI. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev. 2003 Jun;124(6):721-31. doi: 10.1016/s0047-6374(03)00082-4. PMID: 12782416.
2. A. B. Sinyukhin, G. P. Timoshinov, V. A. Kornilov, and P. D. Shabanov, “P.7.a.006 Delta sleep-inducing peptide analogue corrects the CNS functional state of children treated with antiblastomic therapy,” Eur. Neuropsychopharmacol., vol. 19, pp. S681–S682, Sep. 2009.
3. E. V. Koplik et al., “Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection,” Neurosci. Behav. Physiol., vol. 38, no. 9, pp. 953–957, Nov. 2008
4. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-9. doi: 10.1159/000116143. PMID: 3622582.
5. Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):341-5. PMID: 6895513.
6. Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. doi: 10.1159/000115716. PMID: 6548970.
7. Nakamura A, Nakashima M, Sugao T, Kanemoto H, Fukumura Y, Shiomi H. Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). Eur J Pharmacol. 1988 Oct 18;155(3):247-53. doi: 10.1016/0014-2999(88)90510-9. PMID: 2853064.
8. Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides. 2003 Feb;24(2):307-11. doi: 10.1016/s0196-9781(03)00040-8. PMID: 12668217.

The Difference Between CJC-1295 and CJC-1295 DAC

These two peptides seem similar but are not identical. CJC-1295 is a modified equivalent of the first 29 amino acids of GHRH, chemically identical to other growth hormone analogs like Sermorelin. Meanwhile, CJC-1295 DAC is created by adding the Drug Affinity Complex DAC, to CJC-1295.
DAC is added to CJC-1295 using the lysine linker. The DAC appears to protect CJC-1295 while it circulates in the bloodstream. DAC may ensure the increased half-life of CJC-1295 by allowing the peptide to bind to blood proteins such as Albumin.

The Functions of CJC-1295

CJC-1295 NO DAC appears to function to enhance protein synthesis. The peptide may achieve this by inhibiting the natural process of cellular degradation, thereby increasing protein synthesis. The peptide may also potentially improve lipolytic processes by increasing the rate of synthesis and disintegration. By increasing the lipolytic process, CJC-1295 NO DAC peptide may influence the increased efficiency of fat cell dissolution.

CJC-1295 and Hemorrhagic Shock and GHRH 1-29 Interaction

CJC-1295 NO DAC has been hypothesized to stimulate and improve nerve reflexes within the brain and may modulate blood flow, thereby preventing acute organ failure following hemorrhagic shock. On the other hand, hemorrhagic shock may be an acute condition followed by reduced tissue perfusion and insufficient nutrient and oxygen delivery necessary for cellular functions. Hemorrhagic shock is classified as cardiogenic, hypovolemic, septic, and neurogenic.

CJC-1295 NO DAC and Growth

The peptide is considered a potential enhancing agent for maintaining the normal rate of growth hormone release.^[1] By doing this, the peptide may exert action in cases of abnormal growth in varieties of animal species. Maintaining the normal growth hormone level may be critical to releasing downstream hormones like insulin-like growth factor-2 (IGF-1). CJC-1295 appears to significantly enhance the synthesis of IGF-1. GH, CJC-1295, and IGF-1 collectively influence the pro-inflammatory mechanisms when activated.

In mouse models of GHRH knockout, the exposure to CJC-1295 appeared to reduce growth deficits. Furthermore, CJC-1295 appeared to steadily enhance the total body weight and length.^[2] This study reports that “These findings [indicate that exposure to] CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice.” The peptide also assessed the abnormal response to GRF following obesity.

CJC-1295 and Infertility

Scientists suggest GRF analogs, CJC-1295, might induce ovulation in infertile female species. Data findings imply that ovulation may be solely dependent on IGF-1 and may be regulated by the release and cycling of growth hormones. However, research in mouse models of superovulation suggest that the levels of IGF-1 and growth hormone may increase with ovulation.^[3] These results posit that the exposure to a GH secretagogue like CJC-1295 may induce ovulation. Scientific research also suggests that CJC-1295 NO DAC and other GHRH analogs may impact male infertility by inducing sperm production. However, note that this hypothesis is still undergoing testing.^[4] The researchers report that “these results led to the identification of CJC-1295 as a stable and active hGRF1-29 analogwith an extended plasma half-life.”

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

1. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.
2. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
3. Volpe A, Coukos G, Barreca A, Giordano G, Artini PG, Genazzani AR. Clinical use of growth hormone-releasing factor for induction of superovulation. Hum Reprod. 1991 Oct;6(9):1228-32. doi: 10.1093/oxfordjournals.humrep.a137517. PMID: 1752922.
4. Jetté, Lucie, et al. “hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog.” (2005)
5. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.